Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:4
  • preuzimanja u poslednjih 30 dana:4
članak: 3 od 8  
Back povratak na rezultate
Scripta Medica
2019, vol. 50, br. 2, str. 77-81
jezik rada: engleski
vrsta rada: izvorni naučni članak
objavljeno: 13/08/2019
doi: 10.5937/scriptamed50-22255
Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in treatment of patients with chronic hepatitis C in the Republic of Srpska: A real-life study
(naslov ne postoji na srpskom)
aKlinički centar Republike Srpske, Klinika za infektivne bolesti, Banja Luka, Republika Srpska, BiH + Univerzitet u Banjoj Luci, Medicinski fakultet, Katedra za infektologiju, Republika Srpska, BiH
bKlinički centar Republike Srpske, Klinika za infektivne bolesti, Banja Luka, Republika Srpska, BiH
cUniverzitet u Banjoj Luci, Medicinski fakultet, Katedra za farmakologiju i toksikologiju, Republika Srpska, BiH

e-adresa: antonija@blic.net

Sažetak

(ne postoji na srpskom)
Background: The purpose of this study was to assess the antiviral efficacy and safety of the direct-acting antivirals (DAAs) in therapy of chronic hepatitis C virus (HCV) infection. Methods: This real-life multi-centric study was performed at the Clinic for Infectious Diseases, University Clinical Centre of the Republic of Srpska, Banja Luka and it included a total of 89 patients. All patients received the adequate doses of ombitasvir (OBV)/ paritaprevir (PTV)/ritonavir (RTV) + dasabuvir (DSV) plus ribavirin (RBV). RBV was given to all patients except to those with HCV sub-genotype 1b. DSV was not administered to patients infected with HCV genotype 4. For the majority of patients the treatment duration was 12 weeks. For ten patients with liver cirrhosis the duration of treatment was 24 weeks. Viraemia was assessed at three points in time: at baseline, 12 or 24 weeks after the beginning of treatment (end of treatment response - ETR), and 12 weeks after the end of treatment (sustained viral response - SVR). Results: Complete ETR after 12 weeks of treatment was achieved in 79 patients, while in 10 high-risk patients it was achieved after 24 weeks of treatment. Full SVR was recorded in 88 patients 12 weeks after the end of treatment. This therapy was well tolerated and mild adverse effects were recorded in only 10 patients. Conclusion: Treatment of patients with chronic HCV infection with OBV/PTV/ RTV+ DSV + RBV resulted in excellent antiviral activity and mild adverse events.

Ključne reči

hepatitis C virus; ombitasvir; paritaprevir; ritonavir; dasabuvir; ribavirin

Reference

Alswat, K.A., Babatin, M.A., Abdelrahman, A.A., Al-Hamoudi, W.K., Alghamdi, A.S., Abdo, A., Sanai, F.M. (2016) Treatment of chronic hepatitis C genotype 4-infected patients with ombitasvir/paritaprevir/ritonavir plus ribavirin: Real life data from Saudi Arabia. Hepatology, 64(1 Suppl):974A-975A
Backus, L.I., Belperio, P.S., Shahoumian, T.A., Loomis, T.P., Mole, L.A. (2016) Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. Alimentary Pharmacology & Therapeutics, 44(4): 400-410
Desmond, C.P., Roberts, S.K., Dudley, F., Mitchell, J., Day, C., Nguyen, S., Pianko, S. (2006) Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. Journal of Viral Hepatitis, 13(5): 311-315
European Association for the Study of the Liver (2015) EASL Recommendations on Treatment of Hepatitis C 2015. Journal of Hepatology, 63(1): 199-236
Flisiak, R., Janczewska, E., Wawrzynowicz-Syczewska, M., Wiercinska-Drapalo, A., Zarebska-Michaluk, D., Fleischer-Stepniewska, K., et al. (2015) Efficacy and safety of Parytaprewir/r/Ombitaswir and Dazabuwir with or without Ribavirin in real life therapy of Polish patients with chronic hepatitis C: An interim analysis of AM-BER study data. Clin Exp Hepatol, 1(2): 84-84
Flisiak, R., Janczewska, E., Wawrzynowicz-Syczewska, M., Jaroszewicz, J., Zarębska-Michaluk, D., Nazzal, K., Bolewska, B., Bialkowska, J., Berak, H., Fleischer-Stępniewska, K., Tomasiewicz, K., Karwowska, K., Rostkowska, K., Piekarska, A., Tronina, O., Madej, G. (2016) Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. Alimentary Pharmacology & Therapeutics, 44(9): 946-956
Lawitz, E., Makara, M., Akarca, U.S., Thuluvath, P.J., Preotescu, L.L., Varunok, P., Morillas, R.M., Hall, C., Mobashery, N., Redman, R., Pilot-Matias, T., Vilchez, R.A., Hézode, C. (2015) Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients with Genotype 1b Chronic Hepatitis C Virus Infection with and Without Cirrhosis. Gastroenterology, 149(4): 971-980.e1
Łucejko, M., Parfieniuk-Kowerda, A., Flisiak, R. (2016) Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection. Expert Opinion on Pharmacotherapy, 17(8): 1153-1164
McCombs, J., McGinnis, J., Fox, S., Tonnu-Mihara, I. (2016) Analysis of the Real-World Effectiveness of Direct Acting Antiviral Treatments for Hepatitis C in a Large Population. Journal of Hepatology, 64(2): S217-S217
Messina, J.P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G.S., Pybus, O.G., Barnes, E. (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology, 61(1): 77-87
Parkin, D.M. (2006) The global health burden of infection-associated cancers in the year 2002. International Journal of Cancer, 118(12): 3030-3044
Petrovic, J., Salkic, N.N., Ahmetagic, S., Stojic, V., Mott-Divkovic, S. (2011) Prevalence of Chronic Hepatitis B and Hepatitis C among First Time Blood Donors in Northeast Bosnia and Herzegovina: An Estimate of Prevalence in General Population. Hepatitis Monthly, 11(8): 629-633
Pogorzelska, J., Flisiak, R. (2016) Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection. Clinical and Experimental Hepatology, 2: 34-37
Rodríguez-Osorio, I., Cid, P., Morano, L., Castro, Á., Suárez, M., Delgado, M., Margusino, L., Meijide, H., Pernas, B., Tabernilla, A., Pedreira, J.D., Mena, Á., Poveda, E. (2017) Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients. Journal of Clinical Virology, 88: 58-61
World Health Organization (WHO) (2017) Hepatitis C: Factsheets 2017. Geneve (CH), [Internet]. [updated 2017 Oct 14, cited 2017 Nov 15]. Available from: htpp://www.who.int/mediacentre/factsheets/fs164/en
World Health Organization (WHO) (2015) Hepatitis C: Factsheets 2014. Geneve (CH), [Internet]. [cited 2015 Jan 15]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/, accessed on: 15.01.2015